<DOC>
	<DOCNO>NCT01785043</DOCNO>
	<brief_summary>Differences endothelial function amongst Sitagliptin Liraglutide Users . A randomized , open-label , parallel-group active control trial</brief_summary>
	<brief_title>Differences Endothelial Function Amongst Sitagliptin Liraglutide Users</brief_title>
	<detailed_description>Randomized , open-label , parallel-group , active control , phase IV study ass efficacy safety 3 month treatment period Liraglutide Sitagliptin type 2 diabetes patient well control maximum tolerate dose metformin.The study design random design one important technique avoid bias clinical trial . The study follow parallel group , open-label design liraglutide administer subcutaneous injection sitagliptin orally tablet . A double-dummy design reject highly complicate phase IV study , bias open-label design lower impact objective variable ( primary endpoint ) could compensate proposed random design.Sitagliptin select active control one prescribed treatment type 2 diabetes patient well control maximum tolerate dose metformin . The study objective assess 3 month therapy consider suitable time identify short-term change flow-mediated vasodilation</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject . ) 2 . Male female patient 45 65 year old 3 . Preexisting type 2 diabetes HbA1c 7.0 9.5 % 4 . Triglycerides &gt; 1.68 mmol/L 5 . HDL cholesterol &lt; 1.29 mmol/L woman &lt; 1.04 mmol/L men 6 . Systolic blood pressure ( SBP ) &lt; 130 mmHg diastolic blood pressure ( DBP ) &lt; 85 mmHg treatment antihypertensive agent 1 . Known suspected hypersensitivity trial product ( ) relate product 2 . Previous participation trial . Participation define randomise . 3 . Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive , male sexually active surgically sterilise , whose partner use adequate contraception 4 . Moderate severe renal dysfunction ( creatinine clearance &lt; 60 ml/min ) 5 . Previous type 2 diabetes treatment apart metformin insulin 6 . Current smoker history smoking within 6 month prior screen . 7 . Evidence overt cardiovascular disease , ( document coronary heart disease , class IIIV congestive heart failure , cerebrovascular disease , peripheral vascular disease ) . 8 . Caffeine intake within 24 hour endothelial function measurement . 9 . Use drug know clinically significant sympathetic parasympathetic effect , determine Investigator . 10 . Initiation change ( dose treatment regimen ) concomitant blood pressurelowering medication within 4 week prior screen throughout day . 11 . The receipt investigational medicinal product within 6 month prior screen . 12 . Presence cancer significant medical condition 13 . Inability follow verbal write instruction</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>DIABETES Mellitus Type 2</keyword>
	<keyword>Difficult control</keyword>
</DOC>